NCT00299390View on ClinicalTrials.gov

Safety and Efficacy Study of a New Chemotherapy Agent to Treat Small Cell Lung Cancer

PHASE2TerminatedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

April 30, 2006

Primary Completion Date

April 30, 2007

Study Completion Date

April 30, 2007

Conditions
Small Cell Lung Carcinoma
Interventions
DRUG

Sagopilone (BAY86-5302, ZK 219477)

Sagopilone; 16 mg/m2 (maximum 32 mg) as 3 hour i.v. infusion

Sponsors

Lead Sponsor

Bayer
All Listed Sponsors
lead

Bayer

INDUSTRY